Oncoscience

Editors-in-Chief

Mikhail V. Blagosklonny

blagosklonny@oncotarget.com
Mikhail.Blagosklonny@roswellpark.org

Roswell Park Cancer Institute, Buffalo, NY

Mikhail V. Blagosklonny, M.D., Ph.D., Professor, Roswell Park Cancer Institute, Buffalo, NY

Dr. Blagosklonny is author of over 200 articles in peer-reviewed journals. He is Associate Editor of Cancer Res, Cell Death Differ, Cancer Biol Ther, Autophagy, Int J Cancer, Am J Pathology, PLOS ONE and Editor-in-Chief of Cell Cycle. His research interests range from molecular and cellular biology to clinical investigations and include signal transduction, cell cycle, cellular senescence, anticancer therapeutics with emphasis on translation of basic science into new anticancer strategies Recently, he extended the study of signal transduction pathways from cancer to aging, revealing potential targets for slowing down aging and age-related diseases.

Andrei V. Gudkov

andrei.gudkov@roswellpark.org

Roswell Park Cancer Institute, Buffalo, NY

Andrei V. Gudkov, PhD, DSci, Professor and Garman Family Chair in Cell Stress Biology, Senior Vice President for Basic Research of Roswell Park Cancer Institute (RPCI), Buffalo, NY. His academic degrees in experimental oncology and molecular biology were received in former USSR from National Cancer Center and Moscow State University. He is co-founder and Chief Scientific Officer of Cleveland BioLabs, Inc. and Tartis, Inc. His area of general research interest includes drug discovery, gene discovery, molecular targets for cancer treatment.

Editorial Board

Cory Abate-Shen

cabateshen@columbia.edu

Columbia University, NY, NY

Cory Abate-Shen, PhD, Professor, Director of Research, Department of Pathology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University, NY

Frederick Alt

alt@enders.tch.harvard.edu

Harvard Medical School, Boston, MA

Frederick W. Alt, Ph.D., member of the National Academy of Sciences, Professor, Harvard Medical School

Dr. Alt is also Investigator, Howard Hughes Medical Inst., Charles A. Janeway Professor of Pediatrics, HMS, Scientific Director, CBRI Institute for Biomedical Research.Fred Alt received a PhD from the Department of Biological Sciences at Stanford University. He is a Howard Hughes Medical Institute investigator, a member of the National Academy of Sciences and the American Academy of Sciences. He is the recipient of He is the recipient of the 2003 Excellence in Mentoring Award from the American Association of Immunologists and the 2004 Clowes Memorial Award from the American Association of Cancer Research. Editorial Boards: Mol. and Cell. Biology; Advances in Immunology; International Immunology; J. Exp. Med.; Current Opinion in Immunology; Immunity (founding Co-editor; 1993-present); Molecular Medicine (Contributing editor; 1997-present); Faculty of 1000 (co-head, Immunology). Honors and Awards: Fox Award, Stanford Univ. (1973); Hirschl Award (1983); Searle Scholar; (1983) Mallinckrodt Scholar; (1984); NIH Merit Award (1991); National Academy of Sciences (1994); American Academy of Microbiology (1994); American Academy of Arts and Sciences (1994); Associate (Foreign) Member, European Molecular Biology Organization (1999); Excellence in Mentoring Award,Association of Immunologists (2003); American Association of Cancer Research B.H.A. Clowes Award (2004); Rabi Shai Shacknai Memorial Prize in Immunology & Cancer Research (2005); Leukemia & Lymphoma Society de Villiers International Achievement Award (2005), Pasarow Foundation Prize in Cancer Research (2005); Irvington Institute Scientific Leadership in Immunology Award (2005); Establishment of Frederick W. Alt Award for New Discoveries in Immunology by the Irvington Institute (2006); National Cancer Institute Alfred Knudson Award in Cancer Genetics(2007).

Dario Altieri

daltieri@wistar.org

Wistar Institute Cancer Center, Philadelphia, PA

Dario Altieri, MD, Robert and Penny Fox Distinguished Professor, Director, The Wistar Institute Cancer Center, Executive Vice President, Chief Scientific Officer, The Wistar Institute, Philadelphia, PA.

Dafna Bar-Sagi

Dafna.Bar-Sagi@nyumc.org

NYU School of Medicine, New York, NY

Dafna Bar-Sagi, Ph.D., Professor and Chair, Department of Biochemistry New York University School of Medicine, 550 First Avenue New York, NY 10016

After earning her undergraduate and master's degree in Biochemistry from Bar-Ilan University in Israel, Dr. Bar-Sagi completed a PhD in Cell Biology at the State University of New York, Stony Brook (SUNY). She received postdoctoral training and eventually served as Senior Staff Investigator at Cold Spring Harbor Laboratory in Long Island. In 1995, she joined the faculty of the Department of Molecular Genetics and Microbiology at SUNY and served as Department Chair from 2003-2006. She relocated to New York University Medical Center in 2006, where she is currently Professor and Chair of the Department of Biochemistry. Dr. Bar-Sagi has published over 100 peer-reviewed articles in leading scientific journals. In 2008, she was appointed Chair of the Scientific Advisory Board of the Pancreatic Cancer Action Network.

Jiri Bartek

jiri.bartek@img.cas.cz

Institute of Cancer Biology, Copenhagen, Denmark

Jiri Bartek, MD., Ph.D., Professor, Head, Department of Cell Cycle and Cancer Danish Cancer Society, Deputy Director, Centre for Genotoxic Stress Research Cancer Institute of Cancer Biology, Copenhagen

He received his M.D. degree from Palacky University in Olomouc, and his Ph.D. degree in Cell Biology from the Institute of Molecular Genetics in Prague, Czech Republic. His main research interests include the molecular mechanisms of mammalian cell-cycle control and responses to DNA damage, and the cancer-predisposing aberrations of these regulatory pathways.

Jiri Bartek has a total of more than 320 publications in peer reviewed journals (about 30-40 in Nature, Science and Cell), with over 26.000 citations. He is currently member of the editorial boards of 10 high-medium impact biomedical journals and has won a number of awards including: (1991,1992) Czech Medical Association Award, (2000) Elected EMBO member, (2002) A. Benzon Prize, (2003) Novo Nordisk Prize, (2003) G.J. Mendel Medal, (2006) Danish Cancer Society Prize

Susan Bates

seb2227@cumc.columbia.edu

National Cancer Institute, NIH, Bethesda, MD

Susan Bates, M.D., Senior Investigator, Head, Molecular Therapeutics Group, Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Building 10, Room 12N226, Bethesda, MD 20892-1906

Stephen Baylin

sbaylin@jhmi.edu

Johns Hopkins University, Baltimore, MD

Stephen B. Baylin, M.D., Professor, Deputy Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Virginia and DK Ludwig Professor of Oncology, Baltimore, MD, USA

Dr. Stephen B. Baylin is professor of oncology and medicine, director of the cancer biology program at the oncology center, and the Virginia and D.K. Ludwig Professor of Cancer Research at The Johns Hopkins University School of Medicine, and the associate director for research at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Dr. Baylin has been a member of committees of the American Cancer Society and the National Institutes of Health, and his multiple honors include a Research Career Development Award from the National Institutes of Health. For the last 20 years, Dr. Baylin has studied the role of epigenetic gene silencing in the initiation and progression of human cancer.

Joseph R. Bertino

bertinoj@rutgers.edu

Cancer Institute of New Jersey, New Brunswick, NJ

Joseph R. Bertino, M.D., Professor of Medicine and Pharmacology, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School

He has been an American Cancer Society professor since 1976. From 1973 to 1986, Dr. Bertino served as director of the Yale Comprehensive Cancer Center, including director of the center and associate director for clinical research. Dr. Bertino has been internationally recognized for his role in finding curative treatments for leukemia and lymphoma. Dr.Bertino has received several awards and honors, including the Rosenthal Award from the American Association of Clinical Research, the Karnofsky Award from the American Society for Clinical Oncology, and the American Cancer Society Medal of Honor. He was the founding editor of the Journal of Clinical Oncology. Currently, he is the associate editor for Cancer Research and Clinical Cancer Research and also the editor of the Encyclopedia of Cancer. Dr. Bertino served as president for the American Society of Clinical Oncology in 1976, and president of the American Association for Cancer Research in 1995-96. Dr. Bertino is the author and co-author of more than 400 scientific publications.

Mina J. Bissell

mjbissell@lbl.gov

Lawrence Berkeley National Laboratory, Berkeley, CA

Mina J. Bissell, PhD, member of the National Academy of Sciences, Distinguished Scientist, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkley, CA

Mina Bissell has been recognized for her lifetime contributions to the fields of breast cancer research, the enhanced role of extracellular matrix (ECM) and the nucleus environment to gene expression in normal and malignant tissues. These works have ushered and have changed some central paradigms that have strengthened the importance of context in the development of cancer.

Maria A. Blasco

mblasco@cnio.es

National Cancer Research Center, Madrid, Spain

Maria A. Blasco, Ph.D., Professor, Director, Spanish National Cancer Research Centre (CNIO), Head of Telomeres and Telomerase Group, Melchor Fernández Almagro nº3, 28029 Madrid, Spain Maria Blasco has received the Josef Steiner Cancer Research, Rey Jaime I, Körber European Science, Alberto Sols and Fundación Lilly Preclinical Research, Awards. She has also been the recipient of the Spanish National "Santiago Ramón y Cajal" Research Award in Biology (2010). Blasco has also been awarded the EMBO Gold Medal and has served on its Council since 2008.

Bruce Blazar

blaza001@umn.edu

University of Minnesota, Minneapolis MN

Bruce R. Blazar, M.D., Professor, University of Minnesota, Minneapolis MN

Bruce R. Blazar is a Regents Professor of Pediatrics, and Chief of the Pediatric Blood and Marrow Transplantation Program. Dr. Blazar is the Director of the University of Minnesota's Clinical and Translational Science Institute.

Judith Campisi

jcampisi@buckinstitute.org

Buck Institute, Novato, CA

Judith Campisi, Ph.D., Professor, Buck Institute for Research on Aging; Senior Scientist, Lawrence Berkeley National Laboratory, 8001 Redwood Boulevard, Novato CA 94945 USA

Webster Cavenee

wcavenee@ucsd.edu

University of California, San Diego, CA

Webster Cavenee, Ph.D., Professor, member of the National Academy of Sciences, President AACR (1998), member of the Institute of Medicine, layreat of numerous highest awards. Webster Cavenee is director of the Ludwig Institute for Cancer Research, San Diego, and distinguished professor at the University of California, San Diego. Department of Cellular & Moecular Medicine, University of California, San Diego 9500 Gilman Drive, MC-0660, La Jolla, CA 92093.

Kenneth Cowan

kcowan@unmc.edu

University of Nebraska Medical Center, Omaha, NE

Kenneth Cowan, M.D., Ph.D., Professor, University of Nebraska Medical Center, Omaha, NE, Director, Eppley Institute, Director, UNMC Eppley Cancer Center.

Dr. Cowan has authored more than 240 papers for scientific journals and has been appointed by President Bush to a six-year term on the National Cancer Advisory Board to help shape cancer policy.

Carlo M. Croce

carlo.croce@osumc.edu

The Ohio State University,Columbus, OH

Carlo M. Croce, MD, Professor, member of the National Academy of Sciences, Director of Comprehensive Cancer Center, Chair, Molecular Virology, Immunology & Medical Genetics, The Ohio State University, Columbus, OH


Honors & Awards

  • 1975 Research Career Development Award, The National Institutes of Health, Bethesda MD
  • 1985 Outstanding Investigator Award, The National Institutes of Health, National Cancer Institute, Bethesda MD
  • 1987 Scientific Award, American Cancer Society, Philadelphia Division
  • 1990 Richard and Hinda Rosenthal Foundation Award, Association for Cancer Research
  • 1992 Eagles Fly for Leukemia Lifetime Achievement Award
  • 1992 Scanno Prize for Medicine
  • 1992 Outstanding Investigator Award, The National Institutes of Health, National Cancer Institute, Bethesda MD
  • 1993 Charles S. Mott Prize, General Motors Cancer Research Foundation
  • 1993 John Scott Award
  • 1994 Robert J. and Claire Pasarow Foundation Cancer Award
  • 1994 Honorary Member, Japanese Cancer Association
  • 1995 CLAS Distinguished Scientist Award
  • 1996 National Academy of Sciences MVIMG
  • 1997 Rudolf Virchow Honorary Lectureship, University of Wurzburg, Germany
  • 1997 Scientific Excellence in Medicine Award, American-Italian Cancer Foundation
  • 1997 The Twenty-Fifth Solomon A. Berson Memorial Lecture, Mt. Sinai School of Medicine, NY
  • 1999 Raymond Bourgine Award and Gold Medal of Paris
  • 1999 The 1999 AACR-Pezcoller International Award for Cancer Research, American Association for Cancer Research
  • 1999 The 1999 Herz Memorial Lecture in Cancer Research, Tel Aviv University
  • 2000 Doctor in Medicine, Honoris Causa, Uppsala University, Sweden
  • 2000 Honor of Merit of Italian Republic
  • 2001 Clavius Award for Achievement in Science and Research
  • 2002 Rod and Ceil Mortel Lecture in Cancer Research, Penn State University
  • 2003 Italian Gold Medal for Public Health, Presented by President Ciampi
  • 2003 President of the Republic Prize, Accademia di Lincei
  • 2003 Golgi Lecture, Accademia Nazionale dei Lincei
  • 2003 Foreign Member, Accademia Nazionale delle Scienze, delta dei XL
  • 2004 Premio Beccaria, A. Serra Foundation for Cancer Research
  • 2005 Gottlieb Award, MD Anderson Cancer Center
  • 2006 G.H.A. Clowes Memorial Award, American Association for Cancer Research

Chi Van Dang

cvdang@jhmi.edu

Johns Hopkins University, Baltimore, MD

Chi Van Dang, M.D., Ph.D. Professor, Vice Dean for Research, the Johns Hopkins University School of Medicine, Baltimore, MD

Dr. Dang has written more than 200 scientific papers. He is senior editor of Cancer Research and serves on the editorial boards of eight other scientific publications, including the Journal of Molecular Medicine, Current Cancer Therapy Reviews, Drug Discovery Today: Disease Mechanisms, Journal of Clinical Investigations, Neoplasia, Clinical and Translational Science and The Vietnamese Medical Journal. Elected to the National Academy of Sciences' Institute of Medicine in 2006, Dr. Dang has received the National Institutes of Health/National Cancer Institute MERIT award and numerous other accolades.

Ronald A. DePinho

RDePinho@mdanderson.org

MD Anderson Cancer Center, Houston, TX

DePinho, MD, member of the National Academy of Sciences, Professor of Medicine, President of the University of Texas MD Anderson Cancer Center.

His recent Awards includes Albert Szent-Gyrgyi Prize for Progress in Cancer Research, 2009; Helsinki Medal, 2007; Albert Einstein College of Medicine Distinguished Alumnus Award, 2004; American Cancer Society Edith A. Pistorino Research Professorship, 2004; Member, Institute of Medicine of the National Academies, 2004; AACR-G.H.A. Clowes Memorial Award, 2003

Brian J. Druker

drukerb@ohsu.edu

Oregon Health Science University, Portland, OR

Brian J. Druker, MD, PhD, member of the National Academy of Sciences, Professor, Oregon Health & Science University, Director, OHSU Knight Cancer Institute, Oregon Health & Science University

Dr. Druker is the director of OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, and professor of medicine. In 2009 he won the Lasker Clinical Award and the Meyenburg Cancer Research Prize for his influential work in the development of STI571, commonly known as Gleevec, for the treatment of Chronic Myeloid Leukemia. Dr. Druker is an investigator of Howard Hughes Medical Institute (HHMI), and was elected to the Institute of Medicine of National Academies in 2003, the American Association of Physician in 2006, and the National Academy of Sciences in 2007.

Michael A. Dyer,

michael.dyer@stjude.org

St. Jude Children's Research Hospital, Memphis, TN

Michael A. Dyer, PhD, Professor/Member, St. Jude Faculty Co-Leader, Developmental Therapeutics for Solid Malignancies Program

Wafik S. El-Deiry

Wafik.ElDeiry@fccc.edu

Penn State Hershey Cancer Institute, Hershey, PA

Wafik S. El-Deiry, M.D., Ph.D. Professor of Medicine, Chief, Hematology/Oncology Rose Dunlap Division Chair in Hematology/Oncology, Associate Director for Translational Research, Cancer Institute, Penn State Hershey Cancer Institute, Hershey, PA Wafik S. El-Deiry is also an American Cancer Society Research Professor, the Rose Dunlap Professor of Medicine. He is among the top most-cited researchers. His paper, "WAF1, a potential mediator of P53 tumor suppression" (Cell, 75[4]: 817-25, 19 November 1993) is among the top 10 most-cited papers of the 1990s. He is Editor-in-Chief of Cancer Biology and Therapy

Steve J. Elledge

elledge_admin@hms.harvard.edu

Harvard Medical School, Boston, MA

Steve J Elledge, Ph.D., Professor, member of the National Academy of Sciences, HHMI investigator, the Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School and and the Division of Genetics at the Brigham and Women’s Hospital, 77 Avenue Louis Pasteur, Boston, MA. He has received many accolades and awards for his ground breaking research, including: the Michael E. Debakey Award for Research Excellence (2002), the American Association of Cancer Research G.H.A. Clowes Memorial Award (2001), the inaugural Paul Mark’s Prize in Cancer Research (2001), the National Academy of Sciences Award in Molecular Biology (2001), the John B. Carter, Jr. Technology Innovation Award (2002), an NIH Merit Award (2003), the Genetics Society of America Medal (2005), the Hans Sigrist International Prize of Bern University (2005), the Dickson Prize in Medicine (2010), the American Italian Cancer Foundation Prize for Scientific Excellence in Medicine (2012) and the Lewis Rosenstiel Award for Distinguished Work in Basic Medical Sciences (2013). In 2003 Dr. Elledge was also elected into the National Academy of Sciences and the American Academy of Arts and Sciences, to the American Academy of Microbiology in 2005, and the Institute of Medicine in 2006.

Andrew Feinberg

afeinberg@jhu.edu

Johns Hopkins University School of Medicine, Baltimore, MD

Andrew Feinberg, MD, MPH, King Fahd Professor of Molecular Medicine Department of Medicine, Department of Oncology and Department of Molecular Biology & Genetics, Johns Hopkins University School of Medicine

Dean W. Felsher

dfelsher@stanford.edu

Stanford University School of Medicine, Stanford, CA

Dean W. Felsher, MD, PhD, Stanford University School of Medicine, Stanford, CA

Paul B. Fisher

pbfisher@vcu.edu

Virginia Commonwealth University, Richmond, VA

Paul B. Fisher, MPh, PhD, Professor and Chairman, Department of Human & Molecular Genetics, Director VCU Institute of Molecular Medicine, Thelma Newmeyer Corman, Chair in Cancer Research, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, 1101 East Marshall Street, Sanger Hall Building, Room 11-015, Richmond, VA 23298-0033

Tito Fojo

atf2116@cumc.columbia.edu

National Cancer Institute, NIH, Bethesda, MD

Antonio Tito Fojo, M.D., Ph.D., Senior Investigator Head, Experimental Therapeutics Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Building 10, Room 12C103 Bethesda, MD 20892

Antonio Giordano

Temple University, Philadelphia, PA

giordano@temple.edu

Antonio Giordano, MD, Ph.D, Professor and Director, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA

He has published over 350 papers on his work in the fields of cell cycle, gene therapy and the genetics of cancer. Giordano has been named a Knight of the Republic of Italy for outstanding achievements in cancer research. In September of 2009, Giordano received the Philip Mazzei "The Bridge" Award from The American University of Rome for his scientific and economic contributions to the United States and Italy. In the past three years, Dr. Giordano's work has been profiled in Philadelphia Magazine, Philadelphia Business Journal, and Science.

Gabriel N. Hortobagyi

ghortoba@mdanderson.org

M. D. Anderson Cancer Center, Houston, TX

Professor Gabriel N. Hortobagyi, M.D., F. A. C.P is currently the Nellie B. Connally Chair in Breast Cancer Research, Director of the Breast Cancer Research program of U. T. M. D. Anderson Cancer Center and Chairman of the Department of Breast Medical Oncology.

Dr Hortobagyi has dedicated all his clinical and research efforts to breast cancer since the completion of his fellowship training at U. T. M. D Anderson Hospital, Houston, Texas in 1976. Over the following 20 years he led the clinical development of numerous new cytotoxic and hormonal agents and has had uninterrupted external support for his clinical research group since the late 1970's. During this time he and his colleagues developed successful curative treatment regimens for locally advanced and inflammatory breast cancer.

Dr Hortobagyi was President of the American Society of Clinical Oncology (2006-2007) and has served on the Board of Directors of ASCO. He has also chaired the International Affairs Committee, the Cancer Education Committee (2000-2001, the Nominating Committee (1999-2001) of ASCO and President of the International Society of Senology (1996-1998)

Since 2007 Dr Hortobagyi has served as Chair of the Southwest Oncology Group Breast Committee and is currently Chair of the National Surgical Adjuvant Breast and Bowel Project Data and Safety Monitoring Committee. He is a corresponding member of the National Academy of Medicine for both Argentina and Mexico and an external member of the National Academy of Sciences, Hungary. Dr Hortobagyi currently serves on the editorial board of 12 journals, has published over 900 articles of which over 600 are original full-length articles in peer-reviewed journals, over 130 book chapters and has edited or co-edited 9 books.

Candace S. Johnson

candace.johnson@roswellpark.org

Roswell Park Cancer Institute, Buffalo, NY

Candace S Johnson, PhD, Deputy Director, Roswell Park Cancer Institute; Professor and Chair, Department of Pharmacology and Therapeutics, Wallace Chair in Translational Research Roswell Park Cancer Institute; Professor of Pharmaceutical Sciences, State University of New York at Buffalo

Dr. Johnson's research interests include translational research to facilitate the efficient application of promising laboratory findings in clinical studies; preclinical design and development of more effective therapeutic approaches to cancer using highly-characterized tumor models; the mechanisms of vitamin D mediated antiproliferative effects either alone or in combination with other cytotoxic agents and the isolation and characterization of tumor-derived endothelial cells with the potential to target for therapeutic intervention. These research projects are funded by a number of grants from the National Cancer Institute and the Department of Defense. Dr. Johnson has authored or co-authored more than 150 journal publications, book chapters and abstracts. She is a member of the National Institutes of Health Reviewers Reserve and has served as a member of the National Cancer Institute (NCI) Experimental Therapeutics-2 study section and the NCI review group Subcommittee A-Cancer Center (Parent Committee). She also is a member of many professional and scientific societies, Associate Editor of Molecular and Cellular Differentiation, Oncology, and Molecular Pharmacology, and member of the editorial board of Oncology Reports, Molecular Cancer Therapeutics and Molecular Pharmacology. In addition, Dr. Johnson provides the basic science interface to a number of clinical studies based on these studies in collaboration with Dr. Donald L. Trump, CEO and President, Roswell Park Cancer Institute.

William G. Kaelin, Jr.

william_kaelin@dfci.harvard.edu

Dana-Farber Cancer Institute, Harvard Univ. Boston, MA

William G. Kaelin Jr., MD, member of the National Academy of Sciences, Professor of Medicine, Harvard Medical School

Dr. Kaelin is a 2010 Canada Gairdner International Award Recipient. He is a Howard Hughes Medical Investigator since 1998, a member of the American Society of Clinical Investigation and the American College of Physicians. He recently served on the National Cancer Institute Board of Scientific Advisors, the AACR Board of Trustees, and the Institute of Medicine National Cancer Policy Board. He is a recipient of the Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center, the Richard and Hinda Rosenthal Prize from the AACR, and a Doris Duke Distinguished Clinical Scientist award. In 2007 he was elected to the Institute of Medicine and in 2010 he was elected to the National Academy of Sciences.

Michael Karin

mkarin@ucsd.edu; karinoffice@ucsd.edu

University of California, Los Angeles, CA

Michael Karin, Ph.D, member of the National Academy of Sciences, Professor of Pharmacology at the University of California, San Diego (UCSD; La Jolla, CA)

Dr. Karin has received numerous awards including the Oppenheimer Award for Excellence in Research from the Endocrine Society, The Herman Beerman Lectureship from the Society of Investigative Dermatology, C.E.R.I.E.S. Research Award for Physiology or Biology of the Skin, The Grossman Lectureship form the American Gastroenterology Association and an American Cancer Society Research Professorship in 1999. Dr. Karin was elected to the National Academy of Sciences in 2005. Dr. Karin also serves on several advisory boards and was cofounder of Signal Pharmaceuticals (currently Celgene).

Scott E. Kern,

sk@jhmi.edu

Johns Hopkins University, Baltimore, MD

Scott E. Kern, M.D., Professor of Oncology, Johns Hopkins University, Baltimore, MD, co-director of the Kimmel Cancer Center Gastrointestinal Cancer Program, Everett and Marjorie Kovler Professor of Pancreas Cancer Research.

Dr. Kern is a molecular geneticist interested in the clonal mutations of cancer, especially pancreatic cancer. His laboratory identified the first human Smad gene, SMAD4, as well as the first cancer mutations in Smad4, BRCA2, and other genes. Current interests include pharmacogenomics, mitotic instability, and the clinical significance of cancer biomarkers.

Guido Kroemer

kroemer@orange.fr

Research Director, INSERM, Paris, France

Guido Kroemer, Research Director, INSERM, Paris, France

Donald W. Kufe

donald_kufe@dfci.harvard.edu

Harvard Medical School, Boston, MA

Donald W. Kufe, MD, Professor, Department of Medicine, Harvard Medical School Leader, Translational Pharmacology and Early Therapeutic Trials Program, Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute, 450 Brookline Avenue Boston, MA, 02215

Sonia Lain

sonia.lain@ki.se

Karolinska Institutet, Stockholm, Sweden

Sonia Lain, PhD, Professor, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Chiang J Li

cli@bidmc.harvard.edu

Boston Biomedical, Boston, MA

Dr. Chiang J. Li, Ph.D., M.D serves as the President, Chief Executive Officer and Chief Medical Officer at Boston Biomedical, Inc. (BBI). Dr. Li serves as an Executive Officer and Head of Global Oncology of Dainippon Sumitomo Pharma Co., Ltd. He is a Founder of Cequent Pharmaceuticals, Inc. He serves as Head of Global Oncology at the DSP Group. Dr. Li served as the Chief Scientific Officer of Boston Biomedical, Inc. which he founded it in November 2006. He is Adjunct Faculty Member at Beth Israel Deaconess Medical Center, Harvard Medical School. He is a recipient of a number of awards and recognitions, and has published numerous highly cited articles in top leading science journals. He has published a number of highly cited articles in over 50 publications including a number of highly cited articles in top journals and holds 30 issued or filed patents. He is a Diplomate of the American Board of Internal Medi Chairman of the Boardine. Dr. Li graduated from the Harvard-MIT Division of Health Science and Technology, received M.D. magna cum laude from Harvard Medical School and completed clinical residency and fellowship at Brigham& Women's hospital, Dana-Farber Cancer Institute, and Beth Israel Deaconess Medical center.

Michael Lisanti

michaelp.lisanti@gmail.com

University of Salford, Salford, UK

Michael Lisanti, M.D. PhD., Professor of Cell Biology, Director of the Breakthrough Breast Cancer Research Unit, School of Cancer & Enabling Sciences, Faculty of Medical & Human Science, The University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK

John S. Lazo

lazo@pitt.edu

University of Pittsburgh, Pittsburgh, PA

John S. Lazo, PhD, Professor, University of Pittsburgh, Pittsburgh, PA

Arnold Levine

alevine@ias.edu

Institute for Advanced Study, Princeton, NJ

Arnold J. Levine, Ph.D. Member of the National Academy, Professor, The Simons Center for Systems Biology in the School of Natural Sciences at the Institute for Advanced Study, Princeton, NJ.

Levine was on the faculty of the Biochemistry Department of Princeton University from 1968 to 1979, when he became chair and professor in the Department of Microbiology at the State University of New York, Stony Brook, School of Medicine. Returning to Princeton University in 1984, he was named Harry C. Wiess Professor in the Life Sciences in the Department of Molecular Biology, a position he held until 1998. He chaired the Department between 1984 and 1996. He was President and Chief Executive Officer of the Rockefeller University in New York City from 1998 to 2002, as well as Heilbrunn Professor of Cancer Biology and laboratory head until joining the Institute in 2002. The recipient of many honors including: the Medal for Outstanding Contributions to Biomedical Research from Memorial Sloan-Kettering Cancer Center (2000); the Keio Medical Science Prize of the Keio University Medical Science Fund, Japan (2000); the Albany Medical Center Prize in Medicine and Biomedical Research (2001); and the Award for Basic Research from the Surgical Society of Oncologists (2003). Levine is a member of the National Academy of Sciences and of the Academy's Institute of Medicine; he is also the author or coauthor of over 300 scientific papers, as well as a book, Viruses (1993). He has served as board member or adviser to numerous scientific organizations and educational institutions, among them the N.J. Biotechnology Institute, the American Cyanamid Corporation, the SUNY Health Sciences Center in Brooklyn, Albert Einstein College of Medicine, the Weizmann Institute,the Huntsman Cancer Center of the University of Utah, and the Institute for Cancer Research in Lausanne, Switzerland.

Carl Maki

carl_maki@rush.edu

Rush Medical College, Chicago, IL

Carl Maki, Ph.D., Associate Professor, Anatomy and Cell Biology, Rush Medical College, 1750 W. Harrison St., Jelke Building, Chicago, IL 60612

Harold L. Moses

hal.moses@vanderbilt.edu

Vanderbilt-Ingram Cancer Center, Nashville, TN

Harold L. Moses, PhD, Professor, Vanderbilt-Ingram Cancer Center, Nashville, TN

Joseph Nevins

j.nevins@duke.edu

Duke University, Durham, NC

Joseph Nevins, PhD, Professor, Duke University, Durham, NC

Pier Paolo Pandolfi,

ppandolf@bidmc.harvard.edu

Harvard Medical School, Boston, MA

Pier Paolo Pandolfi, PhD, Professor, Harvard Medical School, Boston, MA

Nickolas Papadopoulos,

npapado1@jhmi.edu

Johns Hopkins University, Baltimore, MD

Nickolas Papadopoulos, Ph.D. Associate Professor, Department of Oncology, Director of Translational Genetics, Ludwig Center for Cancer Genetics & Therapeutics, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Institutions, CRB1, Room 585, 1650 Orleans Street, Baltimore, MD 21231

Arthur B. Pardee

arthur_pardee@dfci.harvard.edu

Harvard University, Boston, MA

Arthur B. Pardee, Ph.D, member of the National Academy of Sciences,Professor of Biological Chemistry and Molecular Pharmacology Emeritus, Harvard Medical School

Roberto Pili

Roberto.Pili@RoswellPark.org

Roswell Park Cancer Institute, Buffalo, NY

Roberto Pili, M.D., Professor of Oncology, Chief, Genitourinary Section Leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.

Jeffrey Pollard

jeffrey.pollard@einstein.yu.edu

Albert Einstein College of Medicine, Bronx, NY

Jeffrey Pollard, PhD, Professor, Albert Einstein College of Medicine, Bronx, NY

Carol Prives

clp3@columbia.edu

Columbia University, New York, NY

Carol Prives, Ph.D, member of the National Academy of Sciences, Professor, Columbia University, New York, NY

Edward V. Prochownik

prochownikev@upmc.edu

Children's Hospital of Pittsburgh, Pittsburgh, PA

Edward V. Prochownik, MD, PhD, Professor of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Director of Oncology Research, Children's Hospital of Pittsburgh, PA

Neal Rosen, M.D., Ph.D. is a Member in the Department of Medicine and in the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering Cancer Center, where he serves as Head of Developmental Therapeutics. He is also a Professor of Pharmacology, Cell Biology and Medicine at Cornell University Medical School.

John C. Reed

jreed@burnham.org

Burnham Institute, La Jolla, CA

John C. Reed, MD, Ph.D, Professor, President & Chief Executive Officer, Burnham Institute for Medical Research, La Jolla, CA

Neal Rosen

rosenn@mskcc.org

Sloan-Kettering Cancer Center, New York, NY

Neal Rosen, Sloan-Kettering Cancer Center, New York, NY

Davide Ruggero

davide.ruggero@ucsf.edu

University of California, San Francisco, CA

Davide Ruggero Ph.D, Associate Professor, Helen Diller Family Endowed Chair in Basic Research, University of California San Francisco (UCSF), School of Medicine and Department of Urology, Member, UCSF Comprehensive Cancer Center, Mission Bay Campus MC 3110, Helen Diller Family Cancer Research Building, San Francisco, CA 94158

Anil K. Rustgi

anil2@mail.med.upenn.edu

University of Pennsylvania, Philadelphia, PA

Anil K. Rustgi, M.D., Professor, T. Grier Miller Professor of Medicine, Chief, Division of Gastroenterology, University of Pennsylvania, School of Medicine, Director, Center for Molecular Studies in Digestive and Liver Diseases, University of Pennsylvania, School of Medicine, Co-Program Leader, Tumor Biology Program, University of Pennsylvania Abramson Cancer Center, Director, Joint Center for Digestive, Liver and Pancreatic Medicine, University of Pennsylvania, School of Medicine and the Children's Hospital of Philadelphia, PA

Andrew V. Schally

andrew.schally@va.gov

Veterans Affairs Medical Center Miami, FL

Andrew V. Schally won the Nobel Prize for Medicine or Physiology in 1977, for his research into peptide hormone production in the brain. He is currently Distinguished Medical Research Scientist of the Department of Veterans Affairs, Head of the Endocrine, Polypeptide and Cancer Institute Veterans Affairs Medical Center, Research Service Miami, FL and South Florida VA Foundation for Research and Education, Distinguished Leonard Miller Professor of Pathology, Professor Division of Hematology/Oncology and Division of Endocrinology Department of Medicine, Miller School of Medicine, University of Miami, FL.

Dr. Schally was one of a pair of scientists to first isolate several of the communicating chemical links between the brain and the pituitary gland and also determined their structure and succeeded in synthesizing them. Schally’s discoveries have led to many practical clinical applications that are in wide use. He has written over 2,200 publications, more than 1,200 of them since receiving the Nobel Prize. 27 European & South American Universities: M.D.H.C., D.H.C., D.Sc.H.C., D.Nat. Sc. H.C.

Lasker Award 1975

Nobel Prize in Physiology or Medicine, 1977

Gregg L. Semenza

gsemenza@jhmi.edu

Johns Hopkins University, Baltimore, MD

Gregg L. Semenza, M.D., Ph.D, member of the National Academy of Sciences, Professor, Johns Hopkins University School of Medicine, Baltimore, MD

Manuel Serrano

mserrano@cnio.es

National Cancer Research Center, Madrid, Spain

Manuel Serrano, Ph.D., Professor, Programme Director: Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain Manuel Serrano has received numerous awards including the FEBS Anniversary Prize, the Carcinogenesis Young Investigator Award, as well as Spanish awards from Fundación Echevarne, Fundación Banco de Sabadell, and Fundación "Carmen y Severo Ochoa". Manuel Serrano is an elected EMBO Member.

Jeff Settleman

jeffrey@gene.com

Harvard Medical School, Boston, MA

Jeff Settleman, Harvard Medical School, Boston, MA

Charles J. Sherr

sherr@stjude.org

St. Jude Children's Research Hospital, Memphis, TN

Charles J. Sherr, M.D., Ph.D., Professor, member of the National Academy of Sciences, Chair, Tumor Cell Biology, Investigator, Howard Hughes Medical Institute, St. Jude Children's Research Hospital, 262 Danny Thomas Place Memphis, Tennessee 38105. He has received numerous awards: American Academy of Arts and Sciences, American-Italian Cancer Foundation Prize, American Association for the Advancement of Science, the US Institute of Medicine, General Motors Cancer Foundation Mott Prize, AACR Landon Prize for Basic Cancer Research, Bristol Myers-Squibb Achievement Award for Basic Cancer Research, AACR Pezcoller Award

David Sidransky

dsidrans@jhmi.edu

Johns Hopkins University, Baltimore, MD

David Sidransky, M.D., Professor of Otolaryngology, Oncology, Pathology, Urology. Director, Head and Neck Cancer Research, Johns Hopkins Medical Institutions, Baltimore, MD. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world, in the field of oncology during the past decade, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as Vice Chairman of the Board of Directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is the chairman of Tamir and Champions Oncology and also serves on the board of Rosetta Genomics. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as Director (2005-2008) of the American Association for Cancer Research (AACR). He was the chairperson of AACR International Conferences (2006 and 2007) on Molecular Diagnostics in Cancer Therapeutics.

M. Celeste Simon

celeste2@mail.med.upenn.edu

Univ. Pennsylvania, Philadelphia, PA

M. Celeste Simon, Ph.D., Professor, Scientific Director and Investigator, Abramson Family Cancer Research Institute, Investigator, Howard Hughes Medical Institute, Professor, Cell and Developmental Biology, University of Pennsylvania, Perelman School of Medicine, 456 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104-6160

Andrei Thomas-Tikhonenko

andreit@mail.med.upenn.edu

Univ. Pennsylvania, Philadelphia, PA

Andrei Thomas-Tikhonenko, Ph.D., Professor, Mildred L. Roeckle Endowed Chair in Pathology and Chief, Division of Cancer Pathobiology, The Children's Hospital of Philadelphia, Chair, Cancer Biology Graduate Program, Professor of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, 3501 Civic Center Blvd Philadelphia, PA 19104-4399

Donald L. Trump

donald.trump@roswellpark.org

Roswell Park Cancer Institute, Buffalo, NY

Donald L. Trump, MD FACP, President & CEO, Roswell Park Cancer Institute, Professor of Oncology Roswell Park Cancer Institute, Professor of Medicine, University at Buffalo

Roswell Park Cancer Institute is ranked by the US News & World Report and AARP as one of the best Cancer Hospitals in America, by the American Nurses Association as a "Nursing Magnet Hospital" and by The Leapfrog Group as a Top Hospital For Patient Safety and Quality Care.

Dr. Donald L. Trump was appointed President and Chief Executive Officer of Roswell Park Cancer Institute (RPCI) on April 1, 2007. On first coming to RPCI in January 2002, Dr. Trump served as Senior Vice President for Clinical Research; Chair, Department of Medicine; and Co-Principal Investigator (PI) of the Cancer Center Support Grant (CCSG) funded by the National Cancer Institute. He was appointed Associate Institute Director in the fall of 2006 and became President and CEO of RPCI, and PI of the CCSG, in 2007. In addition to his role as President and CEO, Dr. Trump continues his work as a clinical scientist and physician. He leads the Institute’s strong clinical research program in vitamin D-based cancer prevention and treatment, and he cares for patients with prostate cancer and other urologic cancers. He is principal investigator or co-principal investigator on several grants funded by the National Cancer Institute. He holds European and U.S. patents for the use of vitamin D and vitamin D analogs in combination with high-dose chemotherapy. Dr. Trump is past Secretary/Treasurer of the American Society of Clinical Oncology, and is a member of many professional and scientific societies. Together with his collaborator, Dr. Candace Johnson, Deputy Director of RPCI, Dr. Trump has co-edited a recent textbook entitled Vitamin D and Cancer (Springer). In May 2009 he was inducted into the Johns Hopkins University Society of Scholars. He is a reviewer and/or member of the editorial board of prestigious journals, such as the New England Journal of Medicine, Journal of the National Cancer Institute, Cancer, Journal of Urologic Oncology, Clinical Cancer Research, Cure, Oncology, American Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Cancer Research, and Journal of Clinical Oncology. Dr. Trump has authored or co-authored more than 200 journal publications, book chapters and abstracts.

Alexander Varshavsky

avarsh@caltech.edu

California Institute of Technology, Pasadena, CA

Alexander Varshavsky, Ph.D, member of the National Academy of Sciences, Professor, California Institute of Technology, Pasadena, CA

Alexander Varshavsky is a recipient of the Albert Lasker Award for Basic Medical Research, the Wolf Prize in Medicine and the Louisa Gross Horwitz Prize from Columbia University in 2001 for his research on ubiquitination. In 2006 he won the March of Dimes Prize in Developmental Biology and he won the 2007 $1 million Gotham Prize for an original approach to killing cancer cells.

Bert Vogelstein

vogelbe@jhmi.edu

Johns Hopkins University, Baltimore, MD

Bert Vogelstein, M.D., member of the National Academy of Sciences, Professor, Johns Hopkins University, Baltimore, MD

Bert Vogelstein is a Howard Hughes Medical Institute investigator. He has received the Gairdner Foundation International Award, Louisa Gross Horwitz Prize from Columbia University, Prince of Asturias Award for Technical and Scientific Research, and other awards for his research.

Peter K. Vogt

pkvogt@scripps.edu

The Scripps Research Institute, La Jolla, CA

Peter K. Vogt, Ph.D, member of the National Academy of Science, Professor, The Scripps Research Institute, La Jolla, CA

Dr. Vogt is a Professor in the Department of Molecular and Experimental Medicine at The Scripps Research Institute in La Jolla, California. He has received many awards and honors, including the Gregor Johann Mendel Medal, Charles S. Mott Prize, Ernst Jung Prize for Medicine, Bristol Meyers Award, and ICN International Prize in Virology. Dr. Vogt has been invited as a distinguished lecturer by more than twenty leading research institutions in the US, Europe, and Asia, among them the German Cancer Research Center in Heidelberg for the Meyenburg Foundation Lecture, the Princess Takamatsu Foundation, the Alexander von Humboldt Foundation of the Federal Republic of Germany and the Agency for Science, Technology and Research of Singapore. He was also elected an Honorary Member of the Japanese Cancer Association and received an honorary doctorate from the University of Würzburg. Dr. Vogt is an elected member of many prestigious academies, including the American Academy of Arts and Sciences, the National Academy of Sciences, the Institute of Medicine of the National Academies, and the American Academy of Microbiology. He is the recipient of the 5th Annual Szent-Györgyi Prize for Progress in Cancer Research.

Paul Workman

paul.workman@icr.ac.uk

Cancer Research UK Centre for Cancer Therapeutics Sutton, UK

Paul Workman, Cancer Research UK Centre for Cancer Therapeutics Sutton, UK